Were you looking for information on Bevacizumab? Bevacizamab is a common misspelling of bevacizumab.
Bevacizumab (Avastin®) is commonly prescribed to treat certain types of cancer, such as colorectal and non-squamous, non-small cell lung cancer.
In late 2010, the United States Food and Drug Administration (FDA) recommended that bevacizumab's breast cancer approval be removed. Studies have not shown the drug to increase survival in people with breast cancer, and there is not sufficient benefit to outweigh the risks.
This action does not affect bevacizumab's approval for other uses. Healthcare providers may still use bevacizumab to treat breast cancer, although they will be doing so in an "off-label" fashion.
Because the drug binds to and inhibits a certain protein that encourages the growth of new blood vessels, the cancer is essentially "starved" of its blood supply. Bevacizumab is given by injection at your healthcare provider's office. Side effects can include stomach pain, diarrhea, nausea, and fatigue.
(Click Bevacizumab to learn more, including more detail on how the drug works, tips and precautions for those taking it, and what to do it you take an overdose.)